Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) insider John F. Neylan sold 1,445 shares of the company’s stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $7.14, for a total value of $10,317.30. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
John F. Neylan also recently made the following trade(s):
- On Monday, July 24th, John F. Neylan sold 1,214 shares of Keryx Biopharmaceuticals stock. The stock was sold at an average price of $7.27, for a total value of $8,825.78.
Shares of Keryx Biopharmaceuticals, Inc. (NASDAQ KERX) traded down 3.12% on Friday, reaching $6.52. The company had a trading volume of 968,998 shares. The company has a 50-day moving average price of $7.22 and a 200-day moving average price of $6.22. Keryx Biopharmaceuticals, Inc. has a 52-week low of $4.03 and a 52-week high of $8.38. The firm’s market capitalization is $774.25 million.
Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by $0.60. The business had revenue of $15.10 million during the quarter, compared to the consensus estimate of $14.51 million. Keryx Biopharmaceuticals had a negative return on equity of 2,902.87% and a negative net margin of 431.89%. The company’s revenue for the quarter was up 62.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.42) earnings per share. Equities research analysts forecast that Keryx Biopharmaceuticals, Inc. will post ($1.23) EPS for the current fiscal year.
Several institutional investors have recently bought and sold shares of the company. Norges Bank acquired a new position in Keryx Biopharmaceuticals during the fourth quarter worth approximately $9,973,000. Old West Investment Management LLC increased its stake in Keryx Biopharmaceuticals by 295.4% in the first quarter. Old West Investment Management LLC now owns 828,914 shares of the biopharmaceutical company’s stock worth $5,106,000 after buying an additional 619,285 shares during the period. State Street Corp increased its stake in Keryx Biopharmaceuticals by 20.1% in the first quarter. State Street Corp now owns 3,479,370 shares of the biopharmaceutical company’s stock worth $21,432,000 after buying an additional 582,624 shares during the period. Monarch Partners Asset Management LLC purchased a new stake in Keryx Biopharmaceuticals during the second quarter worth $3,059,000. Finally, Chicago Equity Partners LLC purchased a new stake in Keryx Biopharmaceuticals during the second quarter worth $2,756,000. Institutional investors and hedge funds own 57.76% of the company’s stock.
KERX has been the subject of a number of recent research reports. Maxim Group reiterated a “buy” rating and issued a $7.00 target price on shares of Keryx Biopharmaceuticals in a research note on Monday, May 1st. ValuEngine lowered Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, June 2nd. Cowen and Company reiterated a “hold” rating on shares of Keryx Biopharmaceuticals in a research note on Saturday, June 17th. Zacks Investment Research upgraded Keryx Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 target price for the company in a research note on Wednesday, July 12th. Finally, BidaskClub lowered Keryx Biopharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 19th. Seven investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $7.48.
Keryx Biopharmaceuticals Company Profile
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
What are top analysts saying about Keryx Biopharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Keryx Biopharmaceuticals Inc. and related companies.